Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms
Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost discipline.
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago.
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think
Travere Therapeutics (TVTX) is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-approved therapies for this disease.
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.
Options Bears Eye Plummeting Biotech Stock
Biotech stock Travere Therapeutics Inc (NASDAQ:TVTX) is plummeting today, down 32.8% to trade at $22.92 at last glance, after news that the Food & Drug Administration (FDA) has new questions regarding its Filspari application, which could cause a potential delay for the serious kidney disease treatment.
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript
Travere Therapeutics, Inc. ( TVTX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Nivi Nehra - Vice President of Corporate Communications & Investor Relations Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Chief Research Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Laura Chico - Wedbush Securities Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call.
Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago.
